Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05262556 · ClinicalTrials.gov registry record · Phase 1
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
A Phase 1 study of Neuroendocrine Carcinoma and Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Amr Mohamed MD.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05262556 is a Phase 1 study of Neuroendocrine Carcinoma and Gastroenteropancreatic Neuroendocrine Tumor that is active but no longer recruiting, run by Amr Mohamed MD. The registered enrollment target is 15 participants, below the 280-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05262556, a Phase 1 study of Neuroendocrine Carcinoma and Gastroenteropancreatic Neuroendocrine Tumor, is active but no longer recruiting, sponsored by Amr Mohamed MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot study to evaluate the anti-tumor efficacy of this novel combined regimen (NP-101 TQ Formula plus nivolumab and ipilimumab) in the second-line setting for EP-NECA. NP-101 (TQ Formula) (TQ, C10H12O2) is the main bioactive component of the black seed (Nigella sativa, Ranunculaceae family) and has anti-oxidant, anti-angiogenic effects.
Conditions Studied
Interventions
- DRUG NP-101 (TQ Formula)
- DRUG Nivolumab (3mg/kg)
- DRUG Ipilimumab (1mg/kg)
Study Locations (1)
Ohio
- University hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-12-15 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05262556
The ClinicalTrials.gov registry entry for NCT05262556 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (95% lower). The listed sponsor is Amr Mohamed MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Neuroendocrine Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which NP-101 (TQ Formula) is the first listed.
NCT05262556 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05262556 about?
NCT05262556 is a clinical study titled "NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas". A pilot study to evaluate the anti-tumor efficacy of this novel combined regimen (NP-101 TQ Formula plus nivolumab and ipilimumab) in the second-line setting for EP-NECA. NP-101 (TQ Formula) (TQ, C10H12O2) is the main bioactive component of the black seed (Nigella sativa, Ranunculaceae family) and h...
What is the current status of trial NCT05262556?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-12-15. Estimated completion is 2026-06.
What conditions does trial NCT05262556 study?
This clinical trial studies the following conditions: Neuroendocrine Carcinoma, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm, Mixed Neuroendocrine-Non Neuroendocrine Neoplasm.
What interventions are being tested in trial NCT05262556?
The interventions under investigation include: NP-101 (TQ Formula) (DRUG), Nivolumab (3mg/kg) (DRUG), Ipilimumab (1mg/kg) (DRUG).
Who is sponsoring clinical trial NCT05262556?
This trial is sponsored by Amr Mohamed MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05262556 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
ACTIVE NOT RECRUITING · Phase 1
-
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.